General Growth Properties (GGP) Declares $0.19 Quarterly Dividend; 2.7% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- Broadcom shares climb as AI chip financing deal supports rally
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
General Growth Properties (GGP) Tops Q1 FFO by 5c, Offers Guidance
May 2, 2016 4:06 PM EDTGeneral Growth Properties (NYSE: GGP) reported Q1 EPS of $0.40, $0.05 better than the analyst estimate of $0.35.
GUIDANCE:
General Growth Properties sees Q2 2016 FFO of $0.34-$0.36, versus the consensus of $0.36.
General Growth Properties sees FY2016 FFO of $1.52-$1.56, versus the consensus of... More
Ackman defends Valeant, hints at more changes
May 2, 2016 12:38 PM EDTBy Svea Herbst-Bayliss and Caroline Humer
BOSTON/NEW YORK (Reuters) - Billionaire investor William Ackman on Monday mounted a vigorous defense of Valeant Pharmaceuticals (NYSE: VRX), ruling out any sale of the drug company's "crown jewel" assets but saying price cuts and even a new name may be in its future.
Ackman, whose Pershing Square Capital Management owns 9 percent of Valeant, predicted the company would turn around with the help of its new chief executive officer and by selling greater volumes of products instead of just raising the price of its drugs.
... More


